Phuoc-Hanh Le

Mr. Phuoc-Hanh Le


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
EPEmily L. Pfahl
Emily L. Pfahl
NPNooruddin Pracha
Nooruddin Pracha
MEMohamed H. Emlemdi
Mohamed H. Emlemdi
PLPhuoc-Hanh Le
Phuoc-Hanh Le
MMMina S Makary
Mina S Makary
The integration of artificial intelligence (AI) into medicine, oncology, and radiology represents a marked shift in the diagnosis, prognostication, and management of hepatocellular carcinoma (HCC), a malignancy with high global incidence and poor prognosis. This review examines the application of AI, including machine learning (ML) and deep learning (DL), across the spectrum of HCC care. As AI advances, new convolutional neural networks (CNNs) and other models are enhancing diagnostic accuracy, reducing interpretation times, and improving the characterization of liver lesions across major imaging modalities including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). Beyond diagnosis, the transformative role of AI in prognostication is also improving, where AI can now noninvasively predict critical factors such as microvascular invasion, genetic mutation status, tumor recurrence, and treatment response. Furthermore, AI has shown promise in facilitating patient-specific treatment planning by stratifying patients for interventions such as transarterial chemoembolization (TACE) and stereotactic body radiation therapy (SBRT). The review also addresses the emerging fields of pathomics and the use of AI in positron emission tomography (PET), while critically evaluating the cost-effectiveness of these technologies. Despite its promise, the widespread clinical adoption of AI faces challenges, including limited generalizability, maintaining patient privacy, ethical considerations, and the need for robust prospective validation. Ultimately, this review illustrates that the future of HCC management lies in a collaborative, hybrid-intelligence model, where AI-driven insights augment clinical expertise to optimize diagnostic pathways, personalize therapy, and improve patient outcomes.

4 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HGHunter L. Gazda
Hunter L. Gazda
PLPhuoc-Hanh Le
Phuoc-Hanh Le
APAnkit Patel
Ankit Patel
AJArjun Jha
Arjun Jha
MMMina S Makary
Mina S Makary
HCC is the most common primary liver cancer and the third leading cause of cancer-related death overall